GHRH Lyophilised powder for injection Ref.[7658] Active ingredients: Somatorelin

Source: Medicines & Healthcare Products Regulatory Agency (GB)  Revision Year: 2012  Publisher: Ferring Pharmaceuticals Ltd, Drayton Hall, Church Road, West Drayton, UB7 7PS

Pharmacodynamic properties

Pharmacotherapeutic group: Tests for pituitary function
ATC-code: V04CD05

Somatorelin is normally synthesised in the hypothalamus and stimulates the secretion of growth hormone from the pituitary gland. GHRH is the synthetic form of somatorelin and is identical in structure and function to somatorelin released by the human hypothalamus. Somatorelin physiologically increases plasma growth hormone levels.

Pharmacokinetic properties

After intravenous application of different doses of somatorelin in man, the concentrations of somatorelin in plasma increase within 5 minutes to the maximum value, followed by a rapid decrease. The basal values are reached again after 30-40 minutes.

Preclinical safety data

Not applicable.

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.